TAX 327研究中在米托蒽醌治疗后交叉接受多西他赛治疗或反之的患者的生存情况和前列腺特异性抗原（PSA）反应。

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.

作者信息

Berthold D R, Pond G R, de Wit R, Eisenberger M, Tannock I F

机构信息

Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada.

出版信息

Ann Oncol. 2008 Oct;19(10):1749-53. doi: 10.1093/annonc/mdn288. Epub 2008 May 16.

DOI:10.1093/annonc/mdn288

PMID:18487550

Abstract

BACKGROUND

The TAX 327 study compared 3-weekly docetaxel, weekly docetaxel or 3-weekly mitoxantrone, each with prednisone, for 1006 patients with metastatic hormone-refractory prostate cancer. Survival and symptom control were superior following 3-weekly docetaxel as compared with mitoxantrone. At progression, many patients were treated with the other drug. Here, we provide a retrospective report of survival and prostate-specific antigen (PSA) response after second-line therapy.

METHODS

The TAX 327 database provided information about treatment after progression on first-line therapy, and survival has been updated. Investigators were asked to provide information about crossover treatment and serial PSA values.

RESULTS

We identified 232 crossover patients. Median survival after crossover was 10 months and did not depend on direction of crossover. Data on PSA response are available for 96 patients: PSA response (> or =50% reduction) occurred in 15% of 71 men receiving mitoxantrone after docetaxel and in 28% of 25 men receiving docetaxel after mitoxantrone. Median PSA progression-free survival was 3.4 months for mitoxantrone after docetaxel and 5.9 months for docetaxel after mitoxantrone.

CONCLUSIONS

One quarter of men received crossover therapy and survival was similar in the crossover groups. The PSA response rate to docetaxel after mitoxantrone was higher than that for mitoxantrone after docetaxel.

摘要

背景

TAX 327研究比较了每3周一次的多西他赛、每周一次的多西他赛或每3周一次的米托蒽醌与泼尼松联合使用，用于1006例转移性激素难治性前列腺癌患者。与米托蒽醌相比，每3周一次的多西他赛治疗后的生存和症状控制更佳。疾病进展时，许多患者接受了另一种药物治疗。在此，我们提供二线治疗后生存和前列腺特异性抗原（PSA）反应的回顾性报告。

方法

TAX 327数据库提供了一线治疗进展后治疗的信息，且生存情况已更新。研究人员被要求提供交叉治疗和系列PSA值的信息。

结果

我们确定了232例交叉治疗患者。交叉治疗后的中位生存期为10个月，且不取决于交叉治疗的方向。96例患者有PSA反应数据：在多西他赛治疗后接受米托蒽醌的71例男性中，15%出现PSA反应（降低≥50%）；在米托蒽醌治疗后接受多西他赛的25例男性中，28%出现PSA反应。多西他赛治疗后米托蒽醌的中位无PSA进展生存期为3.4个月，米托蒽醌治疗后多西他赛的中位无PSA进展生存期为5.9个月。